EC approves GlaxoSmithKline's acquisition of Pfizer's Consumer Health Business with conditions
The European Commission has approved, under the EU Merger Regulation, the acquisition of Pfizer's Consumer Health Business by GlaxoSmithKline. The decision is conditional upon the global divestment of Pfizer's topical pain management business carried out under the ThermaCare brand.
GlaxoSmithKline (“GSK”) and Pfizer's Consumer Health Business are both manufacturers and suppliers of a variety of consumer healthcare pharmaceuticals, which are typically available to patients without a prescription from a doctor and generally referred to as “over-the-counter” (“OTC”) pharmaceutical products.
Both companies are active in the European Economic Area (“EEA”) in a number of OTC product categories, namely topical pain management (creams, gels, spays and patches to treat pain locally), systemic pain management (products for oral intake targeting pain centrally), cold and flu treatments (e.g. multi-symptom treatments, antitussives), gastrointestinal treatments (e.g. antiacids, antiflatulents, antiulcerants), nutrition and digestive health (e.g. vitamins, supplements, laxatives), as well as sedatives and sleeping aids.
The Commission's investigation
The Commission examined the effects of the proposed transaction on competition in the markets where the activities of the companies overlap.
Based on the investigation, the Commission was concerned that the acquisition would reduce competition for topical pain management products, possibly resulting in price increases in a number of EEA countries, including Austria, Germany, Ireland, Italy and the Netherlands.
In the market for topical pain management products,the Commission found products to be broadly substitutable irrespective of their different format or composition (e.g. patches and gels, medicated or not).
For topical pain management products, GSK is a leading OTC supplier in the EEA with its range of Volta-branded products (including Voltaren, Voltadol, or Voltarol). These products are mainly sold as medicated gel, creams or spray but also as medicated and non-medicated patches. Pfizer is mostly active in the EEA with its range of ThermaCare-branded products, which consists mainly of non-medicated patches.
The proposed remedies
To address these concerns, the companies offered to divest Pfizer's topical pain management business carried out under the ThermaCarebrand globally. This includes all relevant assets that contribute to the current operation or are necessary to ensure the viability and competitiveness thereof.
These assets will have to be divested as a package to one suitable purchaser to be approved by the Commission. The commitments provide in particular for the divestiture of a Pfizer manufacturing facility located in the US, which is dedicated to the production of ThermaCare products, of all intellectual property rights relating to the ThermaCare products and brand, as well as products under development.
These commitments remove almost entirely the overlaps between GSK and Pfizer's Consumer Health Business in the topical pain management category in the EEA.
Therefore, the Commission concluded that the proposed transaction, as modified by the commitments, would no longer raise competition concerns in the EEA. The Commission's decision is conditional upon full compliance with the commitments.
Companies and products
GSK, based in the UK, is a pharmaceuticals company active worldwide in research, development, manufacturing, and marketing in three broad segments, i.e. prescription pharmaceuticals, vaccines, and consumer healthcare products.
Pfizer, based in the US, is a pharmaceuticals company active worldwide in the research, development, manufacturing and marketing of innovative medicines. Pfizer's Consumer Health Businessoffers products in five major areas: (a) pain management; (b) gastrointestinal health; (c) respiratory; (d) dietary supplements, and (e) personal care products (e.g. lip care).
Merger control rules and procedures
The transaction was notified to the Commission on 17 May 2019.
The Commission has the duty to assess mergers and acquisitions involving companies with a turnover above certain thresholds (see Article 1 of the Merger Regulation) and to prevent concentrations that would significantly impede effective competition in the EEA or any substantial part of it.
The vast majority of notified mergers do not pose competition problems and are cleared after a routine review. From the moment a transaction is notified, the Commission generally has a total of 25 working days to decide whether to grant approval (Phase I) or to start an in-depth investigation (Phase II). This deadline is extended to 35 working days in cases where remedies are submitted by the parties, such as in this case.
Latest News from
Rule of law in Poland and Hungary has worsened17/01/2020 12:05:00
The EU’s discussions with Poland and Hungary have not yet led these countries to realign with the EU’s founding values, Parliament warned on Thursday.
Parliament supports European Green Deal and pushes for even higher ambitions16/01/2020 15:25:00
MEPs support the European Green Deal, but highlight challenges, including ensuring a just and inclusive transition and the need for high interim targets.
Brexit: MEPs concerned about citizens' rights16/01/2020 13:25:00
Parliament highlights that assurances are needed on the protection of citizens’ rights to ensure its consent to the Withdrawal Agreement.
Meeting between President von der Leyen and Leo Varadkar, Taoiseach of Ireland16/01/2020 11:48:00
Remarks made at the joint press point (15 January 2020).
Trade/WTO: EU, U.S. and Japan agree on new ways to strengthen global rules on industrial subsidies15/01/2020 13:25:00
In a Joint Statement, representatives of the European Union, the United States and Japan announced their agreement to strengthen existing rules on industrial subsidies and condemned forced technology transfers practices.
EC steps up protection of European intellectual property in global markets10/01/2020 15:20:00
The EC has published the latest report on protection & enforcement of Intellectual Property Rights (IPR) in third countries. IPR infringements worldwide cost European firms €bns in lost revenue and put thousands of jobs at risk. The report identifies three groups of countries on which the EU will focus its action.
Speech by President von der Leyen at the LSE on 'Old friends, new beginnings: building another future for the EU-UK partnership'09/01/2020 12:10:00
In 1950, before our Union was formed, the UK, Italy and Germany were among the ten most populous countries in the world. Today, only one of those is in the top 20.
Eurojust becomes an Agency07/01/2020 12:05:00
Eurojust heralds a new phase in its development, as it officially becomes the European Agency for Criminal Justice Cooperation, with the application of the Eurojust Regulation as the new legal basis.
ESMA extends recognition decisions for 3 UK CCPs in the event of a no-deal Brexit24/12/2019 10:25:00
The European Securities and Markets Authority (ESMA) has announced that it has extended the recognition decisions for the 3 central counterparties (CCPs) established in the UK to reflect the extension of the expiry date of the Implementing Decision (EU) 2018/2031 of the EC on the equivalence of the UK CCP legal framework.